These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34518917)

  • 41. Mutation patterns in essential thrombocythemia, polycythemia vera and secondary myelofibrosis.
    Wanquet A; Courtier F; Guille A; Carbuccia N; Garnier S; Adélaide J; Gelsi-Boyer V; Mozziconacci MJ; Rey J; Vey N; Birnbaum D; Murati A
    Leuk Lymphoma; 2019 May; 60(5):1289-1293. PubMed ID: 30601073
    [No Abstract]   [Full Text] [Related]  

  • 42. Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter.
    Barosi G
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):129-40. PubMed ID: 25189724
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
    Ganly P; Hanrahan V; Baker B; Romeril K
    Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture.
    Tefferi A
    Leuk Res; 2012 Dec; 36(12):1481-9. PubMed ID: 22917768
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.
    Barbui T; Thiele J; Vannucchi AM; Tefferi A
    Blood Cancer J; 2015 Aug; 5(8):e337. PubMed ID: 26832847
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.
    Vannucchi AM; Antonioli E; Guglielmelli P; Pardanani A; Tefferi A
    Leukemia; 2008 Jul; 22(7):1299-307. PubMed ID: 18496562
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection].
    Andrikovics H; Szilvási A; Meggyesi N; Király V; Halm G; Lueff S; Nahajevszky S; Mikala G; Sipos A; Lovas N; Csukly Z; Mátrai Z; Tamáska J; Tordai A; Masszi T
    Orv Hetil; 2007 Feb; 148(5):203-10. PubMed ID: 17344140
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chronic myeloproliferative disorders: the role of tyrosine kinases in pathogenesis, diagnosis and therapy.
    Macdonald D; Cross NC
    Pathobiology; 2007; 74(2):81-8. PubMed ID: 17587879
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients.
    Macedo LC; de Cesare Quintero F; Pagliari-E-Silva S; Pagnano KB; Rodrigues C; de Alencar JB; Sell AM; Visentainer JE
    Blood Cells Mol Dis; 2016 Mar; 57():54-7. PubMed ID: 26852656
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.
    Poodt J; Fijnheer R; Walsh IB; Hermans MH
    Hematol Oncol; 2006 Dec; 24(4):227-33. PubMed ID: 17006961
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent patents of gene mutation relative to JAK/STAT pathway and their implication in myeloproliferative diseases.
    Shi Y; Xu C
    Recent Pat DNA Gene Seq; 2008; 2(3):209-13. PubMed ID: 19075958
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia.
    Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Leone G; Foà R; Larocca LM
    Blood; 2007 Nov; 110(9):3384-6. PubMed ID: 17644735
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
    Chen Y; Fang F; Hu Y; Liu Q; Bu D; Tan M; Wu L; Zhu P
    PLoS One; 2016; 11(4):e0154183. PubMed ID: 27111338
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Do we know more about essential thrombocythemia because of JAK2V617F?
    Harrison C
    Curr Hematol Malig Rep; 2009 Jan; 4(1):25-32. PubMed ID: 20425435
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Myeloproliferative Neoplasms.
    Spivak JL
    N Engl J Med; 2017 Jun; 376(22):2168-2181. PubMed ID: 28564565
    [No Abstract]   [Full Text] [Related]  

  • 57. Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders.
    Langabeer SE; Ni Ainle F; Conneally E; Lawler M
    Ir J Med Sci; 2007; 176(2):105-9. PubMed ID: 17440677
    [TBL] [Abstract][Full Text] [Related]  

  • 58. JAK2 V617F polycythemia vera and essential thrombocythemia: dynamic clinical features associated with long-term outcomes.
    Sureau L; Buors C; Ianotto JC; Boyer F; Tanguy-Schmidt A; Roy L; Cayssials E; Cailly L; Chomel JC; Chauveau A; Orvain C; Mansier O; Ranta D; Robles M; Gyan E; Hérault O; Nimubona S; Marchand T; Lippert E; Riou J; Ugo V; Luque Paz D
    Blood Cancer J; 2022 Apr; 12(4):56. PubMed ID: 35395836
    [No Abstract]   [Full Text] [Related]  

  • 59. Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
    Mesa R; Jamieson C; Bhatia R; Deininger MW; Gerds AT; Gojo I; Gotlib J; Gundabolu K; Hobbs G; Klisovic RB; Kropf P; Mohan SR; Oh S; Padron E; Podoltsev N; Pollyea DA; Rampal R; Rein LA; Scott B; Snyder DS; Stein BL; Verstovsek S; Wadleigh M; Wang ES; Bergman MA; Gregory KM; Sundar H
    J Natl Compr Canc Netw; 2016 Dec; 14(12):1572-1611. PubMed ID: 27956542
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genotype-phenotype interactions in the myeloproliferative neoplasms.
    Godfrey AL; Green AR
    Hematol Oncol Clin North Am; 2012 Oct; 26(5):993-1015. PubMed ID: 23009934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.